25 results on '"Nishina, Tomohiro"'
Search Results
2. Validity and utility of blood tumor mutational burden (bTMB) is dependent on circulating tumor DNA (ctDNA) shed: SCRUM-Japan MONSTAR-SCREEN
3. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
4. BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer
5. Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer
6. Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study
7. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer
8. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial
9. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial
10. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial
11. O3-9-4 - Phase 1b study of first-line Ramucirumab + Platinum + Fluoropyrimidine in Japanese Patients with advanced gastric cancer
12. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
13. MO32-5 Metabolic interaction between gut microbiome and PIK3CA-mutated colorectal cancer: SCRUM-Japan MONSTAR-SCREEN
14. The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5 ′-deoxy-5-fluorouridine
15. O1-6 REVIVE study: An observational study in chemotherapy (CTx) after nivolumab (NIVO) for advanced gastric cancer (AGC)
16. MO38-3 Clinical update with genomic analyses in expansion part of phase 1 study of selective FGFR inhibitor E7090
17. SY17-5 Potential biomarkers for immunotherapy of gastric cancer
18. PS2-2 [Encore] - SUNRISE-DI Study: Decision Impact of the 12-Gene RS Assay on Adjuvant Chemotherapy for Stage II and IIIA/B Colon Cancer
19. P1-060 - A phase II study of nab-PTX in combination with RAM in patients with pre-treated AGC: results of final analysis
20. P-266 - A clinical validation study of RASKET-B: A multiple detection kit for RAS and BRAF gene mutations in colorectal cancer
21. P2-278 - Risk factor analysis of skeletal related events in gastric cancer patients with bone metastasis
22. O2-10-4 - Avelumab (MSB0010718C; anti-PD-L1), in Japanese patients with advanced gastric cancer: results from phase Ib trial
23. ISY-17-5 - Final survival results of a multicenter phase I/II study of TAS-102 with bevacizumab for mCRC (C-TASK FORCE)
24. O3-11-1 - Phase II Study of Bevacizumab Plus Uft/Lv in Elderly Patients with Metastatic Colorectal Cancer(J-Blue): Os Updated
25. Analysis of p16 abnormality by fluorescence in situ hybridization using endoscopic biopsy samples in gastric lymphoma patients: Correlation with therapeuic response
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.